ProShares Ultra Nasdaq Biotechnology ETF Company Profile (NASDAQ:BIB)

About ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB)

ProShares Ultra Nasdaq Biotechnology ETF logoProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in derivatives that have similar daily performance characteristics as the inverse of the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund.

Industry, Sector and Symbol:
  • Sector: Financials
  • Industry: Exchange Traded Funds - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BIB
  • CUSIP: N/A
  • Web: www.proshares.com/
Average Prices:
  • 50 Day Moving Avg: $52.49
  • 200 Day Moving Avg: $48.35
  • 52 Week Range: $35.00 - $58.62
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Misc:
  • Average Volume: 301,292 shs.
 
Frequently Asked Questions for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB)

What is ProShares Ultra Nasdaq Biotechnology ETF's stock symbol?

ProShares Ultra Nasdaq Biotechnology ETF trades on the NASDAQ under the ticker symbol "BIB."

Who are some of ProShares Ultra Nasdaq Biotechnology ETF's key competitors?

How do I buy ProShares Ultra Nasdaq Biotechnology ETF stock?

Shares of ProShares Ultra Nasdaq Biotechnology ETF can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ProShares Ultra Nasdaq Biotechnology ETF's stock price today?

One share of ProShares Ultra Nasdaq Biotechnology ETF stock can currently be purchased for approximately $58.50.


MarketBeat Community Rating for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ BIB)
Community Ranking:  2.0 out of 5 ( )
Outperform Votes:  2 (Vote Outperform)
Underperform Votes:  3 (Vote Underperform)
Total Votes:  5
MarketBeat's community ratings are surveys of what our community members think about ProShares Ultra Nasdaq Biotechnology ETF and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB)
Latest Headlines for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB)
Source:
DateHeadline
thestreet.com logoBIB's Underlying Holdings Could Mean 18% Gain Potential
www.thestreet.com - June 5 at 12:46 PM
thestreet.com logoBIB Makes Bullish Cross Above Critical Moving Average
www.thestreet.com - June 1 at 4:21 PM
finance.yahoo.com logoTrump's Budget Puts Health Stocks Under Pressure
finance.yahoo.com - March 16 at 8:23 PM
finance.yahoo.com logoBiotech is Bubbling Up
finance.yahoo.com - March 15 at 4:13 PM
nasdaq.com logoBIB, BIIB, REGN, ILMN: Large Outflows Detected at ETF
www.nasdaq.com - February 13 at 4:25 PM
blogs.barrons.com logoBiotech Suffered Big Outflows Again Last Week, Pushing Back A Recovery - Barron's (blog)
blogs.barrons.com - January 30 at 3:45 PM
blogs.barrons.com logoBiotech Suffered Big Outflows Again Last Week, Pushing Back A Recovery
blogs.barrons.com - January 30 at 3:45 PM
seekingalpha.com logoRepublicans advancing changes to Obamacare - Seeking Alpha
seekingalpha.com - January 26 at 4:35 PM
investopedia.com logoTrump Foreshadows a Bleak Outlook for Biotech - Investopedia
www.investopedia.com - January 18 at 3:19 PM
investopedia.com logoTrump Foreshadows a Bleak Outlook for Biotech
www.investopedia.com - January 18 at 3:19 PM
blogs.barrons.com logoThe Most-Shorted Stocks In Health Care In 2016 Were... - Barron's (blog)
blogs.barrons.com - January 7 at 4:27 PM
blogs.barrons.com logoThe Most-Shorted Stocks In Health Care In 2016 Were…
blogs.barrons.com - January 6 at 4:14 PM
blogs.barrons.com logoWill Biotech Find Its Footing In 2017? - Barron's (blog)
blogs.barrons.com - January 6 at 2:22 AM
blogs.barrons.com logoWill Biotech Find Its Footing In 2017?
blogs.barrons.com - January 4 at 4:01 PM
blogs.barrons.com logoBiotech ETFs: A Short-Lived Boon From Biogen - Barron's (blog)
blogs.barrons.com - December 9 at 8:59 PM
blogs.barrons.com logoBiotech ETFs: A Short-Lived Boon From Biogen
blogs.barrons.com - December 9 at 8:59 PM
thestreet.com logoProShares UltraPro Nasdaq Biotechnology (UBIO) Enters Oversold Territory
www.thestreet.com - November 2 at 3:30 PM
finance.yahoo.com logoBUZZ-Biotech ETF weakness grows more acute
finance.yahoo.com - October 28 at 11:56 AM
seekingalpha.com logoAvoid Biotech After Brexit
seekingalpha.com - June 28 at 4:02 PM
seekingalpha.com logoBiotech Strategy Following Brexit: Run, Don't Walk
seekingalpha.com - June 27 at 3:28 PM
seekingalpha.com logoBiotechnology: Ready To Move Higher - Much Higher
seekingalpha.com - June 3 at 12:21 PM
investopedia.com logoBIB vs. LABU: Comparing Leveraged Biotech ETFs
www.investopedia.com - May 4 at 9:21 PM
forbes.com logoThe Five Best Stocks To Short In May - Forbes
www.forbes.com - May 3 at 2:58 PM
blogs.barrons.com logoGravity Kills: 40 ETFs Own Big Slugs of Apple - Barron's (blog)
blogs.barrons.com - April 28 at 2:55 PM
seekingalpha.com logoETFs: Price-Change Prospects For SA Readers' 20 Most Popular Funds - Seeking Alpha
seekingalpha.com - April 6 at 2:55 PM
seekingalpha.com logoNear Price-Change Prospects - Best And Worst - For SA Readers' 20 Biggest-Interest ETFs - Seeking Alpha
seekingalpha.com - April 5 at 2:40 PM
forbes.com logoDUST, BIS: Big ETF Outflows
www.forbes.com - April 4 at 2:35 PM
finance.yahoo.com logoNew Strong Buy Stocks for April 4th
finance.yahoo.com - April 4 at 10:14 AM
nasdaq.com logoAre These ETFs Making You An April Fool? - Nasdaq
www.nasdaq.com - April 2 at 2:44 PM
thestreet.com logoThe Implied Analyst 12-Month Target For BIB
www.thestreet.com - March 22 at 2:31 PM
nasdaq.com logoBetter To Short Biotech ETF Or To Invest In Inverse Counterpart?
www.nasdaq.com - March 16 at 2:44 PM
seekingalpha.com logoIs It A Bull Or Bubble? - Seeking Alpha
seekingalpha.com - March 11 at 1:44 PM
forbes.com logoIs The Biotech Bear Market Over?
www.forbes.com - February 29 at 9:43 PM

Social

Chart

ProShares Ultra Nasdaq Biotechnology ETF (BIB) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by MarketBeat.com Staff